Literature DB >> 21459799

Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.

Wei Dai1, Jens M Teodoridis, Constanze Zeller, Janet Graham, Jenny Hersey, James M Flanagan, Euan Stronach, David W Millan, Nadeem Siddiqui, Jim Paul, Robert Brown.   

Abstract

PURPOSE: Wnt pathways control key biological processes that potentially impact on tumor progression and patient survival. We aimed to evaluate DNA methylation at promoter CpG islands (CGI) of Wnt pathway genes in ovarian tumors at presentation and identify biomarkers of patient progression-free survival (PFS). EXPERIMENTAL
DESIGN: Epithelial ovarian tumors (screening study n = 120, validation study n = 61), prospectively collected through a cohort study, were analyzed by differential methylation hybridization at 302 loci spanning 189 promoter CGIs at 137 genes in Wnt pathways. The association of methylation and PFS was examined by Cox proportional hazards model.
RESULTS: DNA methylation is associated with PFS at 20 of 302 loci (P < 0.05, n = 111), with 5 loci significant at false discovery rate (FDR) less than 10%. A total of 11 of 20 loci retain significance in an independent validation cohort (n = 48, P ≤ 0.05, FDR ≤ 10%), and 7 of these loci, at FZD4, DVL1, NFATC3, ROCK1, LRP5, AXIN1, and NKD1 genes, are independent from clinical parameters (adjusted P < 0.05). Increased methylation at these loci associates with increased hazard of disease progression. A multivariate Cox model incorporates only NKD1 and DVL1, identifying two groups differing in PFS [HR = 2.09; 95% CI (1.39-3.15); permutation test P < 0.005]. Methylation at DVL1 and NFATC3 show significant association with response. Consistent with their epigenetic regulation, reduced expression of FZD4, DVL1, and ROCK1 is an indicator of early-disease relapse in an independent ovarian tumor cohort (n = 311, adjusted P < 0.05).
CONCLUSION: The data highlight the importance of epigenetic regulation of multiple promoter CGIs of Wnt pathway genes in ovarian cancer and identify methylation at NKD1 and DVL1 as independent predictors of PFS. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459799      PMCID: PMC3431504          DOI: 10.1158/1078-0432.CCR-10-3021

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  64 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 2.  Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy.

Authors:  Yingqun Wang
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 3.  Wnt/beta-catenin signaling pathway as a novel cancer drug target.

Authors:  Hue H Luu; Ruiwen Zhang; Rex C Haydon; Elizabeth Rayburn; Quan Kang; Weike Si; Jong Kyung Park; Hui Wang; Ying Peng; Wei Jiang; Tong-Chuan He
Journal:  Curr Cancer Drug Targets       Date:  2004-12       Impact factor: 3.428

4.  Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Authors:  Laura J Havrilesky; Clark M Whitehead; Jennifer M Rubatt; Robert L Cheek; John Groelke; Qin He; Douglas P Malinowski; Timothy J Fischer; Andrew Berchuck
Journal:  Gynecol Oncol       Date:  2008-06-27       Impact factor: 5.482

5.  Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs.

Authors:  Albert Ricken; Paul Lochhead; Maria Kontogiannea; Riaz Farookhi
Journal:  Endocrinology       Date:  2002-07       Impact factor: 4.736

Review 6.  Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers.

Authors:  Ying Ying; Qian Tao
Journal:  Epigenetics       Date:  2009-07-25       Impact factor: 4.528

7.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

8.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

Review 9.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 10.  DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.

Authors:  Paul P Anglim; Todd A Alonzo; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

View more
  42 in total

1.  The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Authors:  Fang Fang; Joanne Munck; Jessica Tang; Pietro Taverna; Yinu Wang; David F B Miller; Jay Pilrose; Gavin Choy; Mohammad Azab; Katherine S Pawelczak; Pamela VanderVere-Carozza; Michael Wagner; John Lyons; Daniela Matei; John J Turchi; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

2.  A 10-gene expression signature of Notch pathway predicts recurrence in ovarian carcinoma.

Authors:  Fang Chen; Naifu Liu
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

3.  Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients.

Authors:  Yu-Ping Liao; Lin-Yu Chen; Rui-Lan Huang; Po-Hsuan Su; Michael W Y Chan; Cheng-Chang Chang; Mu-Hsien Yu; Peng-Hui Wang; Ming-Shyen Yen; Kenneth P Nephew; Hung-Cheng Lai
Journal:  Hum Mol Genet       Date:  2013-11-20       Impact factor: 6.150

Review 4.  Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.

Authors:  Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

5.  Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.

Authors:  Rui-Lan Huang; Fei Gu; Nameer B Kirma; Jianhua Ruan; Chun-Liang Chen; Hui-Chen Wang; Yu-Ping Liao; Cheng-Chang Chang; Mu-Hsien Yu; Jay M Pilrose; Ian M Thompson; Hsuan-Cheng Huang; Tim Hui-Ming Huang; Hung-Cheng Lai; Kenneth P Nephew
Journal:  Epigenetics       Date:  2013-05-10       Impact factor: 4.528

6.  Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.

Authors:  Wei Dai; Constanze Zeller; Nahal Masrour; Nadeem Siddiqui; James Paul; Robert Brown
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

Review 7.  Frizzled homolog proteins, microRNAs and Wnt signaling in cancer.

Authors:  Koji Ueno; Hiroshi Hirata; Yuji Hinoda; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2012-08-30       Impact factor: 7.396

Review 8.  DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art.

Authors:  Frank Roossink; Steven de Jong; G Bea A Wisman; Ate G J van der Zee; Ed Schuuring
Journal:  Cell Oncol (Dordr)       Date:  2012-07-27       Impact factor: 6.730

Review 9.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

10.  Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.

Authors:  Chen Wang; Mine S Cicek; Bridget Charbonneau; Kimberly R Kalli; Sebastian M Armasu; Melissa C Larson; Gottfried E Konecny; Boris Winterhoff; Jian-Bing Fan; Marina Bibikova; Jeremy Chien; Viji Shridhar; Matthew S Block; Lynn C Hartmann; Daniel W Visscher; Julie M Cunningham; Keith L Knutson; Brooke L Fridley; Ellen L Goode
Journal:  Cancer Res       Date:  2014-04-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.